Compare TransMedics Group Inc (TMDX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Williams-Sonoma, Inc. — how do they compare? TransMedics Group Inc trades at $74.78 (market cap $2.54B), while Williams-Sonoma, Inc. trades at $220.79 (market cap $26.30B). The key difference: Williams-Sonoma, Inc. is far larger — about 10.4× TransMedics Group Inc's market cap, and Williams-Sonoma, Inc. pays a 1.36% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WSM | |
|---|---|---|
Market Cap | $2.54B | $26.30B |
Sector | Technology | Consumer Cyclical |
52-Week High | $150.42 | $240.06 |
52-Week Low | $61.99 | $168.64 |
Enterprise Value | $2.94B | $27.14B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Williams-Sonoma (WSM) trades at $223.34, down 2.22% today, with a bullish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with 13.81% net margins and 54.01% ROE, though revenue has declined from $8.7B in 2023 to $7.7B in 2025. Recent earnings beats and consistent dividend payments highlight operational strength amid competitive retail pressures.
WSM presents a mixed outlook with solid fundamentals but faces revenue headwinds and high valuation multiples. Analyst consensus is cautious with 60.72% hold ratings and a $215.22 price target below current levels. Key risks include consumer discretionary spending volatility and execution challenges in maintaining premium positioning against competitors like RH.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
